reason report
show switch data ep despit soft soliri
bottom line morn alexion announc ep
versu consensu versu estim driven
lower oper expens despit soliri sale come
estim consensu within press releas alexion
also disclos posit top-line result phase pnh switch
studi demonstr non-inferior soliri
base primari endpoint ldh reduct alexion
plan file bla approv us eu mid-
year alexion report total pro-forma revenu versu
consensu versu forecast soliri
revenu versu consensu
versu estim soliri revenu increas yoy
qoq sale strensiq
consensu estim kanuma sale
consensu estim
respect total non-gaap expens versu
consensu versu estim driven lower cost
quarter alexion tax rate lower
consensu expect report non-gaap ep
versu consensu versu
estim basi result alexion revis
guidanc tighten revenu guidanc increas
earn forecast expect stock reaction mix
base result posit data strong ep figur
offset slightli soft sale number soliri
alexion disclos within press releas pnh-switch
studi achiev primari endpoint non-inferior soliri
measur ldh reduct addit non-inferior soliri
four key secondari endpoint includ breakthrough hemolysi
qualiti life measur transfus avoid hemoglobin
stabil alexion note numer superior
primari key secondari endpoint also encourag
disclosur zero subject treat experienc
breakthrough hemolysi versu subject treat soliri term
safeti discontinu due advers event neutral
antibodi case meningococc infect alexion provid
detail data medic meet later year
recent wilson transact provid pipelin boost earlier
month alexion announc reach deal acquir rare
diseas drug develop wilson therapeut million cash
payment transact expect close lead drug
patient us follow posit phase ii result small
single-arm studi current phase studi
pleas refer page import disclosur price chart analyst certif
provid top line data potenti modest contributor
top-line growth alexion beyond
guidanc revis base oper perform
well recent transact acquir wilson
expect close alexion revis full-year
guidanc alexion expect total product revenu
versu prior estim
compar current consensu total revenu
guidanc contain estim foreign currenc benefit
soliri guidanc versu
previous current consensu soliri guidanc
contain unfavor impact on-going
studi metabol franchis guidanc lift
 sg expens rang remain unchang
respect well anticip oper
margin alexion expect effect tax rate
versu prior estim current consensu
alexion also rais ep guidanc rang
previous current consensu ep
topic compani upcom confer
call et passcod like
commentari switch studi result on-going launch
soliri mg addit color recent event phase
pnh-naiv result brazilian litig soliri
transact acquir wilson therapeut
sale non-gaap
share count period dilut
guidanc
